Immunocore

Immunocore

Primary Menu

  • About us
    • Management Team
    • Board of Directors
    • Partners
  • Our science
    • Pipeline
    • Publications
    • Scientific Advisory Board
  • Our therapy areas
    • Oncology
    • Infectious Diseases
    • Autoimmune and Inflammation Diseases
  • For patients
  • Investors/Media
  • News
  • Careers
  • Contact us

Primary Menu

  • About us
  • Our science
  • Our therapy areas
  • For patients
  • Investors/Media
  • News
  • Careers
  • Contact us
  1. Home
  2. /
  3. News

News

  • 16 July 2019

    Detailed Review of Tebentafusp (IMCgp100) in Metastatic Uveal Melanoma Published in Issue of Cancers
  • 3 June 2019

    New Biomarker Research Builds Further Understanding of Tebentafusp (IMCgp100) Mechanism of Action, Link to Clinical Activity in Advanced Melanoma
  • 30 May 2019

    Immunocore to present at the Jefferies 2019 Global Healthcare Conference in New York
  • 16 May 2019

    Immunocore to Present New Tebentafusp (IMCgp100) Data in Advanced Melanoma at Upcoming 2019 ASCO Annual Meeting
  • 13 May 2019

    Immunocore Launches Campaign to Educate Physicians on Rare Eye Cancer
  • 7 May 2019

    Immunocore appoints Dr Mohammed Dar as Head of Clinical Development and Chief Medical Officer
  • 3 April 2019

    Immunocore’s Lead Asset Tebentafusp Gains Fast Track Designation for Metastatic Uveal Melanoma
  • 15 January 2019

    Immunocore names David Berman as Head of R&D
  • 4 January 2019

    Immunocore appoints Bahija Jallal as Chief Executive Officer
  • 19 November 2018

    Immunocore to co-develop IMC-C103C, a T cell redirecting bi-specific biologic, with Genentech
  • ← Previous
  • 1
  • 2
  • 3 (current)
  • 4
  • 5
  • 6
  • 7
  • …
  • 11
  • Next →

Sign up to receive news email alerts

News archive
  • Show all
  • 2021 (8)
  • 2020 (8)
  • 2019 (13)
  • 2018 (10)
  • 2017 (13)
  • 2016 (11)
  • 2015 (20)
  • 2014 (6)
  • 2013 (11)
  • 2012 (3)
  • 2011 (1)
  • 2010 (4)
  • 2009 (1)
  • 2008 (1)

Immunocore

Immunocore
  • About us
  • Our science
  • Our therapy areas
  • For patients
  • Investors/Media
  • News
  • Careers
  • Contact us
  • Privacy and Social Media Guidelines
  • Cookies
  • Payments and Disclosures
  • Clinical trials

©2021 Immunocore, Ltd. All rights reserved. ImmTAC, ImmTAV, ImmTAB, ImmTAAI and ImmTAX are all registered trademarks of Immunocore, Ltd